What is the purpose of this trial?
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with MS201408-0005C or MS201408-0005B (Part IB, Part IC).
EMD Serono, Inc.
Dates: 02/22/2018 - 07/05/2019
Last Updated: 03/07/2018
Study HIC#: 2000021715